JP2021511386A5 - - Google Patents

Info

Publication number
JP2021511386A5
JP2021511386A5 JP2020561591A JP2020561591A JP2021511386A5 JP 2021511386 A5 JP2021511386 A5 JP 2021511386A5 JP 2020561591 A JP2020561591 A JP 2020561591A JP 2020561591 A JP2020561591 A JP 2020561591A JP 2021511386 A5 JP2021511386 A5 JP 2021511386A5
Authority
JP
Japan
Prior art keywords
glucagon
minutes
therapeutic agent
agent according
less
Prior art date
Application number
JP2020561591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021511386A (ja
JPWO2019147718A5 (https=
JP7444786B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/014815 external-priority patent/WO2019147718A1/en
Publication of JP2021511386A publication Critical patent/JP2021511386A/ja
Publication of JP2021511386A5 publication Critical patent/JP2021511386A5/ja
Publication of JPWO2019147718A5 publication Critical patent/JPWO2019147718A5/ja
Application granted granted Critical
Publication of JP7444786B2 publication Critical patent/JP7444786B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561591A 2018-01-23 2019-01-23 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置 Active JP7444786B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620861P 2018-01-23 2018-01-23
US62/620,861 2018-01-23
PCT/US2019/014815 WO2019147718A1 (en) 2018-01-23 2019-01-23 Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon

Publications (4)

Publication Number Publication Date
JP2021511386A JP2021511386A (ja) 2021-05-06
JP2021511386A5 true JP2021511386A5 (https=) 2022-01-31
JPWO2019147718A5 JPWO2019147718A5 (https=) 2022-01-31
JP7444786B2 JP7444786B2 (ja) 2024-03-06

Family

ID=65352189

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561591A Active JP7444786B2 (ja) 2018-01-23 2019-01-23 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置

Country Status (9)

Country Link
US (1) US20210030847A1 (https=)
EP (1) EP3743097A1 (https=)
JP (1) JP7444786B2 (https=)
KR (1) KR20200134213A (https=)
CN (1) CN111936159A (https=)
AU (1) AU2019211352A1 (https=)
BR (1) BR112020014719A2 (https=)
MX (1) MX2020007768A (https=)
WO (1) WO2019147718A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026899A1 (en) * 2016-08-03 2018-02-08 Joslin Diabetes Center, Inc. Methods and compositions for treating hypoglycemia
US12543982B2 (en) 2021-01-22 2026-02-10 Cilag Gmbh International Method of adjusting a surgical parameter based on biomarker measurements
US12569203B2 (en) * 2021-01-22 2026-03-10 Cilag Gmbh International Bariatric surgery post-surgical monitoring
US12527515B2 (en) 2021-01-22 2026-01-20 Cilag Gmbh International Colorectal surgery post-surgical monitoring
US12128089B2 (en) * 2022-05-26 2024-10-29 Slayback Pharma Llc Stable liquid compositions of glucagon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2552952A1 (en) 2010-03-26 2013-02-06 Novo Nordisk A/S Novel glucagon analogues
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
JP2014510739A (ja) * 2011-03-28 2014-05-01 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
AU2013295035B2 (en) * 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
DK3102184T3 (da) 2014-02-06 2019-05-06 Xeris Pharmaceuticals Inc Stabile formuleringer af peptider og fremgangsmåder til fremstilling
MY185334A (en) * 2014-12-30 2021-05-06 Hanmi Pharm Ind Co Ltd Glucagon derivatives with improved stability
AU2016267052B2 (en) * 2015-05-22 2022-01-20 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with GLP-1 antagonists
WO2016196976A1 (en) * 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
AU2016304588A1 (en) * 2015-08-06 2018-02-15 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia

Similar Documents

Publication Publication Date Title
JP2021511386A5 (https=)
JP6763777B2 (ja) 安定なペプチド製剤、および調製のための方法
JP5794736B2 (ja) 迅速取込みのためのインスリン製剤
AU2017200295B2 (en) Stable formulations for parenteral injection of peptide drugs
JP6835831B2 (ja) 非プロトン性極性溶媒中の安定な治療用グルカゴン製剤を製造するための方法
RU2311922C2 (ru) Свободные от цинка и обедненные цинком инсулиновые композиции с повышенной стабильностью
CN101912600B (zh) 改善胰岛素在溶液中稳定性的方法
US20180036411A1 (en) Stable Formulation of Insulin Glulisine
KR20140146209A (ko) 인슐린 및 인슐린 유사체의 약동학 및 약역학과 주사 통증을 조절하기 위한 마그네슘 조성물
US20150065423A1 (en) Rapid acting injectable formulations
US20250057923A1 (en) Systems, compositions and methods for treating diabetes
CN107949374A (zh) 稳定的胰高血糖素溶液
JP2023156297A (ja) 先天性高インスリン症を処置する方法
CN107106659B (zh) 肠胃外胰高血糖素制剂
JPWO2019147718A5 (https=)
US9155695B2 (en) Injectable ropinirole compositions and methods for making and using same
US20220354782A1 (en) Subcutaneously injectable insulin and glucagon formulations and methods of administration
HK40101667A (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
HK40101667B (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
CN103655468B (zh) 一种促胰岛素分泌肽融合蛋白Exendin-4-HSA溶液稳定制剂
HK40025146A (en) Methods for treating congenital hyperinsulinism
HK1250644B (en) Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents